ErbB2 _ HER2 Antibody (Antigen Affinity Purified)
- Known as:
- ErbB2 _ HER2 Antibody (Antigen Affinity Purified)
- Catalog number:
- 10004-RP04
- Product Quantity:
- 100
- Category:
- -
- Supplier:
- Smart Serology
- Gene target:
- ErbB2 _ HER2 Antibody (Antigen Affinity Purified)
Related genes to: ErbB2 _ HER2 Antibody (Antigen Affinity Purified)
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: ErbB2 _ HER2 Antibody (Antigen Affinity Purified)
Related articles to: ErbB2 _ HER2 Antibody (Antigen Affinity Purified)
- Brain metastases (BM) significantly affect both prognosis and quality of life in patients with metastatic non-small cell lung cancer (NSCLC), highlighting the need for innovative therapeutic strategies. In this systematic review, we evaluated the prevalence and clinical significance of key genomic alterations in BM from NSCLC. - Source: PubMed
Publication date: 2026/03/12
Wang TingXing HangHuang LeiZhuang HaoZhang JianguoGe HongZhang BoCao YueZhai YiningZheng XiaoliBu ShanshanAbbas Abbas EHadfield MatthewCarneiro Benedito ACheng LiangLiu Yifei - This study aims to investigate the pharmacological effects and potential mechanisms of dehydrocorydaline, the primary active component of W.T. Wang, as a potential therapeutic agent for pancreatic cancer, thereby providing new insights into its treatment. The pharmacological effects were assessed through MTT assay, colony formation assay, flow cytometry, scratch wound assay, and transwell assay. Potential mechanisms were explored through bioinformatics analysis and Western blot. Dehydrocorydaline was verified to stimulate apoptosis and inhibit the growth, migration, and invasion of pancreatic cancer BxPC-3 cells. These effects may be associated with suppressed HSP90α expression, induced ERBB2 degradation, and subsequent inhibition of STAT3 and PI3K/Akt/mTOR pathway activation, as well as altered expression of multiple downstream proteins. This study demonstrates that dehydrocorydaline is the main active component of W.T. Wang with anti-pancreatic cancer activity. Based on protein expression-level evidence, it may exert its effects by inhibiting HSP90α expression and inducing ERBB2 degradation, thereby affecting the PI3K/Akt/mTOR and STAT3 pathways, ultimately suppressing proliferation, migration, and invasion while promoting apoptosis in BxPC-3 cells. These findings justify further investigation of dehydrocorydaline as a potential treatment for pancreatic cancer. - Source: PubMed
Publication date: 2026/05/29
Yu QingmengLi RuidingLi ZhengyuWan ZhexinLv KaikaiHe ChongyangSun JianfangJia ShubingXu YijiaZhao Mingyi - HER2DX is a 27-gene genomic assay generating three complementary scores: a pCR score predicting the likelihood of achieving pathological complete response (pCR, defined as absence of residual invasive disease after neoadjuvant therapy), a Risk score estimating long-term recurrence risk, and an mRNA score quantifying HER2 transcriptional activation. Together, these scores may guide treatment escalation or de-escalation strategies in routine practice. We performed a single-center observational study at 12 de Octubre University Hospital (Madrid, Spain), including patients with early-stage HER2-positive breast cancer who underwent HER2DX testing (2023-2025), and analyzed clinicopathologic features, treatment decisions, and pathological outcomes. Forty-five patients were included (median age 57 years). Stage II accounted for 71.1% of cases; 66.7% were hormone receptor-positive, and 31.3% were node-positive. HER2DX modified clinical management in 51.1% of patients. The pCR score changed the initial strategy (neoadjuvant therapy versus upfront surgery) in 17.8% of cases and, independently, favored de-escalation to taxane plus dual HER2 blockade, with 90% of high-score tumors achieving a pathological complete response. The Risk score informed chemotherapy backbone selection within stage II disease. The score correlated with HER2 immunohistochemical intensity. In this exploratory real-world cohort, HER2DX provided biologically distinct information beyond traditional immunohistochemistry and was associated with modifications in multidisciplinary treatment decision-making in early-stage HER2-positive breast cancer, warranting prospective validation in larger cohorts. - Source: PubMed
Publication date: 2026/06/11
Nogueira Lola RMaderuelo AnaAlva Bianchi ManuelTolosa PabloLema LauraMontes JuanZumárraga TeresaMadariaga AinhoaManso LuisAragón Sánchez SofíaSanz ConsueloRuano YolandaCiruelos Gil EvaSánchez-Bayona Rodrigo - HER2 overexpression and/or amplification defines a molecularly distinct subset of endometrial carcinomas (ECs) that may benefit from HER2-targeted therapies. However, HER2 testing algorithms remain non-standardized and vary across institutions. This study is a large single-institution audit of EC HER2 testing practices, using both gynecologic (ISGyP) and gastric cancer-specific scoring algorithms at a major academic center with a reference gynecologic oncology service and biomarker laboratory. - Source: PubMed
Publication date: 2026/06/22
Nofech-Mozes SharonOlkhov-Mitsel EkaterinaLu Fang-IHuang Weei-YuarnPlotkin Anna - The incidence of Ampullary carcinoma (AC) has dramatically increased. Nearly 50% of patients develop recurrence indicating need for additional prognostic markers and treatment options. Emerging evidence suggests that Mesenchymal Epithelial Transition (MET) genes play a role in tumorigenesis and can be a useful therapeutic target, however, its role in AC remains unexplored. - Source: PubMed
Publication date: 2026/06/25
Apurva Kumar ArunSharma Abhay KumarNimisha Ahmad EjajBatra Vineeta VijaySantoshi SenehaSaluja Sundeep Singh